Health Care [ 4/12 ] | Life Sciences Tools & Services [ 64/75 ]
NASDAQ | Common Stock
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution.
It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | -0.29 Increased by +21.62% | -0.31 Increased by +6.45% |
| Nov 6, 25 | -0.32 Increased by +8.57% | -0.31 Decreased by -3.23% |
| Aug 6, 25 | -0.33 Increased by +5.71% | -0.36 Increased by +8.33% |
| Jun 12, 25 | -0.34 Decreased by -6.25% | -0.30 Decreased by -13.33% |
| Feb 26, 25 | -0.37 Decreased by -32.14% | -0.39 Increased by +4.42% |
| Nov 6, 24 | -0.35 Decreased by -6.06% | -0.31 Decreased by -12.90% |
| Aug 8, 24 | -0.35 Increased by +5.41% | -0.36 Increased by +2.78% |
| May 8, 24 | -0.32 Increased by +15.79% | -0.30 Decreased by -6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 4.20 M Increased by +6.38% | -15.99 M Increased by +26.44% | Decreased by -380.72% Increased by +30.85% |
| Sep 30, 25 | 4.12 M Increased by +4.54% | -18.23 M Increased by +14.51% | Decreased by -442.47% Increased by +18.22% |
| Jun 30, 25 | 4.05 M Increased by +31.87% | -19.42 M Increased by +14.99% | Decreased by -479.49% Increased by +35.54% |
| Mar 31, 25 | 4.21 M Increased by +37.15% | -19.95 M Increased by +3.53% | Decreased by -474.39% Increased by +29.66% |
| Dec 31, 24 | 3.95 M Decreased by -5.53% | -21.74 M Decreased by -22.15% | Decreased by -550.57% Decreased by -29.30% |
| Sep 30, 24 | 3.94 M Decreased by -5.29% | -21.33 M Decreased by -1.14% | Decreased by -541.05% Decreased by -6.78% |
| Jun 30, 24 | 3.07 M Decreased by -23.35% | -22.85 M Increased by +2.48% | Decreased by -743.82% Decreased by -27.23% |
| Mar 31, 24 | 3.07 M Decreased by -24.35% | -20.68 M Increased by +13.69% | Decreased by -674.46% Decreased by -14.09% |